Efficacy and safety of erlotinib in elderly patients with non-small-cell lung cancer harboring epidermal growth factor receptor mutations: A phase 2 study.
Not Applicable
- Conditions
- non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000010525
- Lead Sponsor
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria are as follows 1: History of severe allergic reactions to drugs. 2: Pregnancy or lactation. 3: Willing to get pregnant. 4: Interstitial lung disease. 5: Severe infection. 6; Severe and unstable medical comorbidities. 7: Difficulty in ingestion. 8: Uncontrolled brain metastases. 9: EGFR T790M mutation. 10: Judgment to attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method